ArticleFrontiers in veterinary science2022
Design of a multi-epitope vaccine against
Article in Frontiers in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Immunoinformatics-Guided Computational Design and In Silico Validation of Multi-Epitope Vaccine Candidates Targeting Canine and Feline Parvoviruses.Microorganisms · 2026Article
- Global whole-genome, phylodynamic, and machine-learning analysis ofApplied and environmental microbiology · 2026Article
- Proteomics- and immunoinformatics-based design of a multi-epitope vaccine ZZ1 against Glaesserella parasuis.BMC veterinary research · 2026Article
- Integrative 16S rRNA characterization, pan-genome, and immunoinformatics approaches for the design of a multi-epitope vaccine against Bacillus cereus, a foodborne pathogen.World journal of microbiology & biotechnology · 2026Article
- Design of B-Cell Multi-Epitope Subunit Vaccines AgainstTransboundary and emerging diseases · 2026Article
- Research progress onFrontiers in veterinary science · 2025Review
- Immunoinformatics design of an mRNA vaccine against classical swine fever virus using conserved E2 protein and NS3 T-lymphocyte epitopes.BioImpacts : BI · 2025Article
- Evaluation of a multi-epitope vaccine PME forFrontiers in immunology · 2025Article
- Enhanced Systemic and Mucosal Immune Responses toVaccines · 2024Article
- In silico designing of multi-epitope vaccine against canine parvovirus using reverse vaccinology.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Immunoinformatics approach for designing a multiepitope subunit vaccine against porcine epidemic diarrhea virus genotype IIA spike protein.Open veterinary journal · 2024Article
- Immunoinformatics-guided approach for designing a pan-proteome multi-epitope subunit vaccine against African swine fever virus.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glässer's disease, caused by Methods: In the current study, we aimed to identify potential vaccine candidates and design a multi-epitope vaccine against HPS by performing pan-genomic analysis of 121 strains and using a reverse vaccinology approach. Results: The designed vaccine constructs consist of predicted epitopes of B and T cells derived from the outer membrane proteins of the HPS core genome. The vaccine was found to be highly immunogenic, non-toxic, and non-allergenic as well as have stable physicochemical properties. It has a high binding affinity to Toll-like receptor 2. In addition, Conclusion: The overall results of the study suggest that the designed multi-epitope vaccine is a promising candidate for pan-prophylaxis against different strains of HPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.